Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma.
about
Langerhans cell histiocytosis of the thyroid with multiple cervical lymph node involvement accompanying metastatic thyroid papillary carcinoma.The Clinicopathological Features of BRAF Mutated Papillary Thyroid Cancers in Chinese PatientsFirst-Line Use of Vemurafenib to Enable Thyroidectomy and Radioactive Iodine Ablation for BRAF-Positive Metastatic Papillary Thyroid Carcinoma: A Case ReportNo evidence of association between human cytomegalovirus infection and papillary thyroid cancer.Clinical impact of BRAF mutation on the diagnosis and prognosis of papillary thyroid carcinoma: a systematic review and meta-analysis.Unfavorable efficacy to 131I ablation in BRAFV600E mutant papillary thyroid carcinoma with positive TgAb.
P2860
Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma.
@en
type
label
Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma.
@en
prefLabel
Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma.
@en
P2093
P2860
P356
P1476
Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma.
@en
P2093
Ja-Seong Bae
Jeong-Soo Kim
Woo-Chan Park
Yong-Seok Kim
P2860
P2888
P356
10.1186/1477-7819-11-99
P577
2013-05-20T00:00:00Z
P5875
P6179
1025915031